Fmr LLC decreased its stake in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 97.4% during the first quarter, Holdings Channel reports. The fund owned 56,170 shares of the specialty pharmaceutical company’s stock after selling 2,094,199 shares during the period. Fmr LLC’s holdings in Valeant Pharmaceuticals International were worth $620,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in VRX. Raymond James Financial Services Advisors Inc. raised its stake in shares of Valeant Pharmaceuticals International by 61.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 41,414 shares of the specialty pharmaceutical company’s stock valued at $457,000 after buying an additional 15,719 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter valued at about $331,000. Guggenheim Capital LLC raised its stake in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 2,752 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in shares of Valeant Pharmaceuticals International by 2.6% in the first quarter. Pictet Asset Management Ltd. now owns 114,200 shares of the specialty pharmaceutical company’s stock valued at $1,258,000 after buying an additional 2,900 shares during the last quarter. Finally, Academy Capital Management Inc. TX raised its stake in shares of Valeant Pharmaceuticals International by 19.5% in the first quarter. Academy Capital Management Inc. TX now owns 641,738 shares of the specialty pharmaceutical company’s stock valued at $7,078,000 after buying an additional 104,844 shares during the last quarter. Institutional investors and hedge funds own 51.14% of the company’s stock.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) opened at 15.37 on Tuesday. Valeant Pharmaceuticals International, Inc. has a 1-year low of $8.31 and a 1-year high of $32.74. The company’s market cap is $5.35 billion. The firm’s 50-day moving average is $16.16 and its 200 day moving average is $13.34.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The firm had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $2.17 billion. During the same quarter in the previous year, the company posted ($1.08) earnings per share. The company’s revenue was down 11.1% compared to the same quarter last year. Analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

WARNING: “Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Shares Sold by Fmr LLC” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/08/valeant-pharmaceuticals-international-inc-nysevrx-shares-sold-by-fmr-llc.html.

Several equities research analysts have issued reports on VRX shares. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research report on Sunday, July 30th. BidaskClub lowered shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research report on Friday, June 16th. Scotiabank dropped their target price on shares of Valeant Pharmaceuticals International from $15.00 to $12.00 and set a “sector perform” rating for the company in a research report on Wednesday, April 26th. Vetr lowered shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 target price for the company. in a research report on Monday, May 22nd. Finally, Mizuho reiterated an “underperform” rating and set a $8.00 target price (down from $9.00) on shares of Valeant Pharmaceuticals International in a research report on Monday, April 17th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $16.96.

In other news, Director Schutter Richard U. De bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The stock was purchased at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares of the company’s stock, valued at approximately $980,950.80. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 5.87% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.